Document:

EX-10.9

UNSECURED PROMISSORY NOTE (this “Note”)

$ 4,000,000

June 8, 2007 (the “Note Date”)

FOR VALUE RECEIVED, NNN Healthcare/Office REIT Holdings, L.P., a Delaware limited partnership
(“Borrower”), unconditionally promises to pay NNN Realty Advisors, Inc., a Delaware corporation
(“Lender”), in the manner and at the place hereinafter provided, the principal amount of Four
Million Dollars ($4,000,000).

Borrower also promises to pay interest on the unpaid principal amount hereof from the Note
Date until paid in full at a rate per annum equal to the Interest Rate (capitalized terms used
herein and not otherwise defined herein shall have the meanings provided in Schedule A
attached hereto), provided that any principal amount not paid when due and, to the extent permitted
by applicable law, any interest not paid when due, in each case whether at stated maturity,
declaration, acceleration, demand or otherwise (both before as well as after judgment), shall bear
interest payable upon demand at a rate per annum equal to the Default Interest Rate. Interest on
this Note shall be payable in arrears on the first day of each month beginning on the Commencement
Date, each date on which an installment of principal is due and payable hereunder, upon any
prepayment of this Note (to the extent accrued on the amount being prepaid) and at maturity. All
computations of interest shall be made by Lender on the basis of a 365-day year, for the actual
number of days elapsed in the relevant period (including the first day but excluding the last day).
In no event shall the interest rate payable on this Note exceed the maximum rate of interest
permitted to be charged under applicable law.

1. Maturity Date. The outstanding principal amount of the Note, and any accrued but
unpaid interest thereon, shall be automatically due and payable on the Maturity Date.

2. Payments. All payments of principal and interest in respect of this Note shall be
made in lawful money of the United States of America in same day funds at the office of Lender
located at 1551 N. Tustin Avenue, Suite 200, Santa Ana, California 92705, or at such other place as
Lender may direct. Whenever any payment on this Note is stated to be due on a day that is not a
Business Day (as defined herein), such payment shall instead be made on the next Business Day and
such extension of time shall be included in the computation of interest payable on this Note. Each
payment made hereunder shall be credited first to interest then due and the remainder of such
payment shall be credited to principal, and interest shall thereupon cease to accrue upon the
principal so credited. Each of Lender and any subsequent holder of this Note agrees, by its
acceptance hereof, that before disposing of this Note or any part hereof the Lender and any
subsequent holder of this Note will mutually agree on the amount of all principal payments
previously made hereunder and of the date to which interest hereon has been paid; provided,
however, that the failure to make a notation of any payment made on this Note shall not
limit or otherwise affect the obligation of Borrower hereunder with respect to payments of
principal or interest on this Note. “Business Day” means any day other than a Saturday, Sunday or
legal holiday under the laws of the State of California or any other day on which banking
institutions located in such state are authorized or required by law or other governmental action
to close.

3. Prepayments. Borrower shall have the right at any time and from time to time on or
prior to the Maturity Date to prepay the principal of this Note in whole or in part, without
premium or penalty. Any prepayment hereunder shall be accompanied by the payment of accrued
interest on the principal amount of the Note being prepaid to the date of prepayment.

4. Covenants. Borrower covenants and agrees that until this Note is paid in full it
will:

(a) promptly provide to Lender financial and operational information with respect to
Borrower or any of its subsidiaries as Lender may reasonably request;

(b) promptly after the occurrence of an Event of Default (as defined herein) or an
event, act or condition that, with notice or lapse of time or both, would constitute an
Event of Default, provide Lender with a certificate of the chief executive officer, chief
financial officer or general partner(s) of Borrower specifying the nature thereof and
Borrower’s proposed response thereto; and

(c) not merge or consolidate with any other Person (as defined herein), or sell, lease
or otherwise dispose of all or any substantial part of its property or assets to any other
Person.

“Person” means any individual, partnership, limited liability company, joint venture, firm,
corporation, association, bank, trust or other enterprise, whether or not a legal entity, or any
government or political subdivision or any agency, department or instrumentality thereof.

5. Representations and Warranties. Borrower hereby represents and warrants to Lender
that:

(a) it is a duly organized and validly existing corporation in good standing under the
laws of the jurisdiction of its organization and has the corporate power and authority to
own and operate its properties, to transact the business in which it is now engaged and to
execute and deliver this Note;

(b) this Note constitutes the duly authorized, legally valid and binding obligation of
Borrower, enforceable against Borrower in accordance with its terms;

(c) all consents and grants of approval required to have been granted by any Person in
connection with the execution, delivery and performance of this Note have been granted;

(d) the execution, delivery and performance by Borrower of this Note do not and will
not violate any law, governmental rule or regulation, court order or agreement to which it
is subject or by which its properties are bound or the charter documents or bylaws of
Borrower;

(e) there is no action, suit, proceeding or governmental investigation pending or, to
the knowledge of Borrower, threatened against Borrower or any of its subsidiaries or any of
their respective assets which, if adversely determined, would have a material adverse effect
on the business, operations, properties, assets, condition (financial or otherwise) or
prospects of Borrower and its subsidiaries, taken as a whole, or the ability of Borrower to
comply with its obligations hereunder; and

(f) the proceeds of the loan evidenced by this Note shall be used by Borrower for the
purpose of acquiring real property.

6. Events of Default. The occurrence of any of the following events shall constitute
an “Event of Default”:

(a) failure of Borrower to pay any Installment Payment or interest thereon due under
this Note within five business days after the date due, or failure of Borrower to pay any
principal, interest or other amount due under this Note when otherwise due, whether at
stated maturity, declaration, acceleration, demand or otherwise; or

(b) failure of Borrower to perform or observe any other term, covenant or agreement to
be performed or observed by it pursuant to this Note; or

(c) any representation or warranty made by Borrower to Lender in connection with this
Note shall prove to have been false in any material respect when made; or

(d) any order, judgment or decree shall be entered against Borrower decreeing the
liquidation, dissolution or split-up of Borrower; or

(e) suspension of the usual business activities of Borrower or the complete or partial
liquidation of Borrower’s business; or

(f) (i) a court having jurisdiction in the premises shall enter a decree or order for
relief in respect of Borrower in an involuntary case under Title 11 of the United States
Code entitled “Bankruptcy” (as now and hereinafter in effect, or any successor thereto, the
“Bankruptcy Code”) or any applicable bankruptcy, insolvency or other similar law now or
hereafter in effect, which decree or order is not stayed, or any other similar relief shall
be granted under any applicable federal or state law, or (ii) an involuntary case shall be
commenced against Borrower under any applicable bankruptcy, insolvency or other similar law
now or hereafter in effect, or a decree or order of a court having jurisdiction in the
premises for the appointment of a receiver, liquidator, sequestrator, trustee, custodian or
other officer having similar powers over Borrower or over all or a substantial part of its
property shall have been entered, or the involuntary appointment of an interim receiver,
trustee or other custodian of Borrower for all or a substantial part of its property shall
have occurred, or a warrant of attachment, execution or similar process shall have been
issued against any substantial part of the property of Borrower and, in the case of any
event described in this clause (ii), such event shall have continued for 60 days unless
dismissed, bonded or discharged; or

(g) an order for relief shall be entered with respect to Borrower or Borrower shall
commence a voluntary case under the Bankruptcy Code or any applicable bankruptcy, insolvency
or other similar law now or hereafter in effect, or shall consent to the entry of an order
for relief in an involuntary case, or to the conversion of an involuntary case to a
voluntary case, under any such law, or shall consent to the appointment of or taking
possession by a receiver, trustee or other custodian for all or a substantial part of its
property, or Borrower shall make an assignment for the benefit of creditors, or Borrower
shall be unable or fail, or shall admit in writing its inability, to pay its debts as such
debts become due, or the board of directors or general partner(s) of Borrower (or any
committee thereof) shall adopt any resolution or otherwise authorize action to approve any
of the foregoing; or

(h) Borrower shall challenge, or institute any proceedings to challenge, the validity,
binding effect or enforceability of this Note or any endorsement of this Note or any other
obligation to Lender; or

(i) any provision of this Note or any provision hereof or thereof shall cease to be in
full force or effect or shall be declared to be null or void or otherwise unenforceable in
whole or in part.

7. Remedies. Upon the occurrence of any Event of Default specified in Section
6(g) or 6(h) above, and upon Borrower’s receipt of written notice of any Event of
Default from Lender, the principal amount of this Note, together with accrued interest thereon,
shall become immediately due and payable. Upon the occurrence and during the continuance of any
other Event of Default, Lender may, by written notice to Borrower, declare the principal amount of
this Note, together with accrued interest thereon, to be due and payable, and the principal amount
of this Note, together with such interest, shall thereupon immediately become due and payable
without presentment, further notice, protest or other requirements of any kind (all of which are
hereby expressly waived by Borrower). From and after any Event of Default until such time as the
Event of Default has been cured, the Default Interest Rate shall be applicable.

8. Miscellaneous.

(a) All notices and other communications provided for hereunder shall be in writing
(including telefacsimile communication) and mailed, telecopied or delivered by overnight
courier as follows: if to Borrower, at its address specified opposite its signature below
and, if to Lender, at Lender’s address in Section 2 above or, in each case, at such
other address as shall be designated by Lender or Borrower. All such notices and
communications shall, when mailed, telecopied or delivered by overnight courier, be
effective when deposited in the mails, sent by telecopier or delivered to the overnight
courier, as the case may be.

(b) Borrower shall indemnify Lender against any losses, claims, damages and liabilities
and related expenses, including counsel fees and expenses, incurred by Lender arising out of
or in connection with or as a result of the transactions contemplated by this Note. In
particular, Borrower shall pay all costs and expenses, including reasonable attorneys’ fees,
incurred in connection with the collection and enforcement of this Note.

(c) No failure or delay on the part of Lender or any other holder of this Note to
exercise any right, power or privilege under this Note and no course of dealing between
Borrower and Lender shall impair such right, power or privilege or operate as a waiver of
any default or an acquiescence therein, nor shall any single or partial exercise of any such
right, power or privilege preclude any other or further exercise thereof or the exercise of
any other right, power or privilege. The rights and remedies expressly provided in this
Note are cumulative to, and not exclusive of, any rights or remedies that Lender would
otherwise have. No notice to or demand on Borrower in any case shall entitle Borrower to
any other or further notice or demand in similar or other circumstances or constitute a
waiver of the right of Lender to any other or further action in any circumstances without
notice or demand.

(d) Borrower and any endorser of this Note hereby consent to renewals and extensions of
time at or after the Maturity Date, without notice, and hereby waive diligence, presentment,
protest, demand and notice of every kind and, to the full extent permitted by law, the right
to plead any statute of limitations as a defense to any demand hereunder.

(e) THIS NOTE AND THE RIGHTS AND OBLIGATIONS OF BORROWER AND LENDER HEREUNDER SHALL BE
GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE INTERNAL LAWS OF
THE STATE OF CALIFORNIA, WITHOUT REGARD TO CONFLICTS OF LAWS PRINCIPLES.

(f) ALL JUDICIAL PROCEEDINGS BROUGHT AGAINST BORROWER ARISING OUT OF OR RELATING TO
THIS NOTE MAY BE BROUGHT IN ANY STATE OR FEDERAL COURT OF COMPETENT JURISDICTION IN THE
STATE OF CALIFORNIA, AND BY EXECUTION AND DELIVERY OF THIS NOTE BORROWER ACCEPTS FOR ITSELF
AND IN CONNECTION WITH ITS PROPERTIES, GENERALLY AND UNCONDITIONALLY, THE NONEXCLUSIVE
JURISDICTION OF THE AFORESAID COURTS AND WAIVES ANY DEFENSE OF FORUM NON CONVENIENS AND
IRREVOCABLY AGREES TO BE BOUND BY ANY JUDGMENT RENDERED THEREBY IN CONNECTION WITH THIS
NOTE. Borrower hereby agrees that service of all process in any such proceeding in any such
court may be made by registered or certified mail, return receipt requested, to Borrower at
its address set forth below its signature hereto, such service being hereby acknowledged by
Borrower to be sufficient for personal jurisdiction in any action against Borrower in any
such court and to be otherwise effective and binding service in every respect. Nothing
herein shall affect the right to serve process in any other manner permitted by law or shall
limit the right of Lender to bring proceedings against Borrower in the courts of any other
jurisdiction.

(g) BORROWER AND, BY THEIR ACCEPTANCE OF THIS NOTE, LENDER AND ANY SUBSEQUENT HOLDER OF
THIS NOTE HEREBY IRREVOCABLY AGREE TO WAIVE THEIR RESPECTIVE RIGHTS TO A JURY TRIAL OF ANY
CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS NOTE OR ANY DEALINGS BETWEEN THEM
RELATING TO THE SUBJECT MATTER OF THIS NOTE AND THE LENDER/BORROWER RELATIONSHIP THAT IS
BEING ESTABLISHED. The scope of this waiver is intended to be all-encompassing of any and
all disputes that may be filed in any court and that relate to the subject matter of this
transaction, including, without limitation, contract claims, tort claims, breach of duty
claims and all other common law and statutory claims. Borrower and, by their acceptance of
this Note, Lender and any subsequent holder of this Note each (i) acknowledges that this
waiver is a material inducement to enter into a business relationship, that each has already
relied on this waiver in entering into this relationship and that each will continue to rely
on this waiver in their related future dealings, and (ii) further warrants and represents
that each has reviewed this waiver with its legal counsel and that each knowingly and
voluntarily waives its jury trial rights following consultation with legal counsel. THIS
WAIVER IS IRREVOCABLE, MEANING THAT IT MAY NOT BE MODIFIED EITHER ORALLY OR IN WRITING, AND
THIS WAIVER SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS OR MODIFICATIONS
OF THIS NOTE. In the event of litigation, this provision may be filed as a written consent
to a trial by the court.

(h) Borrower hereby waives the benefit of any statute or rule of law or judicial
decision, including without limitation California Civil Code § 1654, which would otherwise
require that the provisions of this Note be construed or interpreted most strongly against
the party responsible for the drafting thereof.

[Remainder of page intentionally left blank]

1

IN WITNESS WHEREOF, Borrower has executed and
delivered this Note as of the Note Date at Lender’s address.

“Borrower”

NNN HEALTHCARE/OFFICE REIT HOLDINGS, L.P., a
Delaware limited partnership

	 	 	 	By:
NNN HEALTHCARE/OFFICE REIT, INC., a
Maryland corporation, its general partner

/s/ Shannon K S Johnson

	 	 	 
	By:

	 	Shannon K S Johnson

	 	 	 
	Its:	 	Chief Financial Officer

Address: 1551 N. Tustin Avenue, Suite 200

Santa Ana, CA 92705

“Lender”

NNN REALTY ADVISORS, Inc., a Delaware
corporation

/s/ Francene LaPoint

	 	 	 
	 	 	By:	 	 	Francene LaPoint
	 	 	Its:	 	 	Chief Financial Officer

2

SCHEDULE A

DEFINED TERMS

The following terms used in the Note shall have the following meanings (and any of such terms
may, unless the context otherwise requires, be used in the singular or the plural depending on the
reference):

	 	 	 
	Defined Term	 	Definition
	Commencement Date	 	July 1, 2007
	Maturity Date

	 	December 8, 2007
	 

	 	 
	 
	 	 
	Interest Rate

	 	6.82% per annum.
	 

	 	 
	 
	 	 
	Default Interest Rate

	 	The rate that is 2% per annum in excess of the

Interest Rate.
	 

	 	 
	 
	 	 

3Exhibit 10.1

                                                                    06011-001

                         EXCLUSIVE OPTION AGREEMENT

   This Exclusive Option Agreement (hereinafter called "Agreement"), to be
effective as of the 15th day of March, 2007 (hereinafter called "Effective
Date"), is by and among The Cleveland Clinic Foundation (hereinafter, "CCF")
with its principal location at 9500 Euclid Ave., Cleveland, Ohio 44195 and
IVPSA, with its principal location at 500 N. Rainbow, Suite 300, Las Vegas,
NV 89107 (hereinafter, "OPTIONEE"). Collectively, both entities may
hereinafter be referenced to as "Party" or "Parties."

RECITALS:
---------

   Whereas, CCF owns the Licensable Technology as defined below;

   Whereas, OPTIONEE specializes in developing technology and bringing new
technologies to market;

   Whereas, OPTIONEE desires to investigate and conduct due diligence with
respect to the commercial viability of the Licensable Technology prior to
executing the License Agreement;

   NOW, THEREFORE, for and in consideration of the premises and other good
and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, and intending to be legally bound hereby, the Parties hereto
expressly agree as fellows:

1.   DEFINITIONS
     -----------

   A. "Affiliates" means any corporation or other business entity which
controls, is controlled by or is under common control with OPTIONEE. For
purposes of this Section 1.1, "control" shall mean direct or indirect
ownership of (i) at least fifty percent (50%) of the outstanding stock or
other voting rights entitled to elect directors, or (ii) in any country where
the local law shall not permit foreign equity participation of at least fifty
percent (50%) then the maximum percentage of such outstanding stock or voting
rights permitted by local law.

   B. "Confidential Information" means any confidential or proprietary
information furnished by one party (the "Disclosing Party") to the other
party (the "Receiving Party") in connection with this Agreement, provided
that such information is specifically designated as confidential.
Confidential Information shall include, but not be limited to, the following
when specifically designated as confidential: business information, trade
secrets, technical information, know-how, engineering process, intellectual
property, business plans and strategies, business operations and systems,
marketing techniques, material pricing policies, information concerning
employees, customers, licensees and/or vendors, patent applications, patent
prosecution, inventions, ideas, procedures, formulae or data, The term
Confidential Information shall not be deemed to include information which (a)
is now, or hereafter becomes, through no act or failure of the Receiving
Party, in the public domain; (b) is known by the Receiving Party at the time
of receipt of such information; (c) is hereafter furnished to the Receiving
Party by a. third party, who is not subject to any restriction on disclosure
at the time of disclosure to the Receiving Party; or (d) has been developed
by the Receiving Party completely independent of the delivery of Confidential
Information hereunder.

   C. "Field" shall mean clinical use as a catheter for insertion into the
vascular system of a patient to direct fluid flow, sampling of fluids and
oxygenation monitoring.

                                      1 of 7
<PAGE>

   D. "Licensable Know How" shall mean any and all information, including but
not limited to, confidential, proprietary and trade secret information owned,
controlled, originated, conceived, reduced to practice, developed or
otherwise in the possession of CCF as of the Effective Date necessary to
practice Licensable Patents, including without limitation, all methods,
processes, processing techniques, products, compositions, formulas, test
data, and designs.

   E. "Licensable Patents" shall refer to and mean US Patent Application #
60/797,433 entitled "Intra-jugular Catheter" and any U.S. or foreign patent
applications, reissues, extensions, renewals, reexaminations, certificates of
invention, substitutions, divisions, continuations, and continuations-in-part
thereof having the Principal Investigator as an inventor and having the same
priority date as the parent applications.

   G. "Licensable Technology" shall mean Licensable Patents and Licensable
Know How,

   H. "Principal Investigator" shall mean Dr. Rafi Avitsian while an employee
of CCF.

2.   OPTION GRANT
     ------------

   2.1 Option Period For a period of twelve (12) months immediately following
       -------------
the Effective Date of this Agreement ("Option Period"), CCF agrees that it
will not enter into any exclusive agreement with any third party with
respect to the transfer of rights in the Field to the Licensable
Technology, whether by license or otherwise,

   2.2 Negotiation for a License Agreement During the Option Period, Parties
       -----------------------------------
shall negotiate a License Agreement having terms and conditions generally
agreeable to CCF not limited to but including an upfront license fee,
milestones and a royalty. Binding obligations for such a license agreement
will only be created by the execution and delivery of a definitive written
agreement between the Parties and shall be dependant on OPTIONEE providing a
product development plan for the Licensable Technology that is acceptable to
CCF at its sole discretion. If an agreement has not been reached within said
Option Period, the parties shall have no further obligations under this
Agreement and CCF shall be free to license any and all rights under the
Licensable Technology to any third party without any further obligation to
OPTIONEE.

   The license agreement shall include at least the following provisions.
license fees, royalty payments, required terms for granting sublicenses (if
any), a commitment by OPTIONEE and any sublicensee to exert their best
efforts to introduce the licensed material into public use as rapidly as
practicable, the right of CCF to terminate the license should OPTIONEE not
meet specified due-diligence milestones, and indemnity and insurance
provisions satisfactory to CCF. Provided other terms of a license agreement
negotiated by the Parties upon OPTIONEE's exercise of the Option generally
conform with CCF's standard practices and license terms, such license
agreement shall include financial terms to be negotiated within the following
ranges: (i) OPTIONEE shall pay CCF a License Fee in amounts that total not
less than seventy-five thousand dollars ($75,000) nor more than one hundred
thousand dollars ($100,000); and (ii) OPTIONEE shall remit royalties to CCF
on a quarterly basis based on a percentage of net sales of the products
subject to the license agreement of not less than 7.5% nor more than 15%.

                                      2 of 7
<PAGE>

3.   PAYMENTS
     --------

   3.1 Option Fee. Within fifteen (l5)days of the Effective Date of this
Agreement, OPTIONEE shall pay CCF a nonrefundable fee equal to thirty-six
thousand dollars ($36,000).

   3.2 Patent Prosecution and Maintenance.  CCF shall notify OPTIONEE of any
and all costs associated with prosecuting and maintaining the Licensable
Patents throughout the Option Period, and OPTIONEE shall reimburse CCF up to
$2,500 any and all reasonable costs associated therewith, Reimbursement
payments shall be due within 15 days of receiving invoices from CCF. If
OPTIONEE fails to make such reimbursement payments, it shall automatically
relinquish all rights under this Agreement.

4.   INTELLECTUAL PROPERTY RIGHTS
     ----------------------------

   Title to all Licensable Technology (including but not limited to
prototypes developed by the OPTIONEE) shall remain in CCF. Any materials
developed by OPTIONEE shall be returned to CCF at the end of the Option
Period.

5.   TERMINATION
     -----------

   5.1 Term Unless otherwise terminated by operation of law or by acts of the
       ----
parties in accordance with the terms of this Agreement, this Agreement
shall automatically terminate upon conclusion of the Option Period.

   5.2 Termination for Breach
       ----------------------

       (a) This Agreement shall be terminable upon the material breach of
either party. In the event of a material breach by a party ("Defaulting
Party") the other party ("Non-Defaulting Party") shall give the Defaulting
Party written notice of the default and its termination of this Agreement,
subject to a thirty (30) day right to cure. If the Defaulting Party (i) fails
to cure the breach within thirty (30) days after receipt of notice from the
Non-Defaulting Party, or (ii) fails to provide a written explanation
satisfactory to the Non-Defaulting Party for the cure or other resolution of
the default, then this Agreement shall be terminated as of the date of the
notice. All termination rights shall be in addition to and not in
substitution for any other remedies that may be available to the Non-
Defaulting Party.

       (b) Termination pursuant to this section shall not relieve the
Defaulting Party from liability and damages to the Non-Defaulting Party for
default. Waiver by either party of a single default or a succession of
defaults shall not deprive such party of any right to terminate this
Agreement arising by reason of a subsequent default

   5.3 Termination Without Cause. Either party may terminate this Agreement
       --------------------------
at any time prior to the expiration of the Option Period, by providing
thirty (30) days written notice of same to the non-terminating party..

   5.4 Effects of Termination. Any termination of this Agreement for any
       -----------------------
reason, does not relieve either party of any obligation or liability accrued
prior to the termination or rescind anything done by either party and the
termination does not affect in any manner any rights of either party arising
under

                                    3 of 7
<PAGE>

this Agreement prior to the termination. Upon expiration of this Agreement,
the obligations set forth in Sections 8, 9.2, 9.3, 9.7 and 9.13, 9.14 shall
survive.

6.   ASSIGNABILITY
     -------------

This Agreement shall be binding upon and shall inure to the benefit of the
Parties and their respective assigns and successors in interest. The
Agreement may not be assigned by either Party without the consent in writing
of the other Party.

7.   ADDRESSES
     ---------

   All notices, reports or other required, material communications pursuant
to this Agreement shall be sent to such Party via (i) United States Postal
Service certified mail, return receipt requested, postage prepaid, (ii)
overnight courier, charges prepaid or (iii) facsimile transmission, addressed
to it at its address set forth below or as it shall designate by written
notice given to the other Parties. Notice shall be sufficiently made or given
(a) on the date of mailing, (b) when deposited with the overnight courier, or
(c) when facsimile printer reflects receipt.

   CCF:

   CCF Innovations - Mailstop D20
   The Cleveland Clinic Foundation
   500 Euclid Avenue
   Cleveland, OH 44195
   Attn: Neil Veloso
   Facsimile No. 216-445-6514

   With copy to:

   Office of General Counsel - Mailstop
   Attn: Karen Shanahan, Esq.
   Facsimile No. 216-297-7005

   OPTIONEE:

   IVPSA
   500 N. Rainbow, Suite 300,
   Las Vegas NV _89107

8.   DISPUTE RESOLUTION
     ------------------

   8.1 Except in the event that a party shall reasonably determine that it
must seek a preliminary injunction, temporary restraining order or other
provisional relief; upon the occurrence of a dispute between parties,
including, without limitation, any breach of this Agreement or any obligation
relating thereto, the matter shall be referred first to authorized officers
of CCF and OPTIONEE, or their designees. The authorized officers or their
designees as the CCF may be, shall negotiate in good faith to resolve such
dispute in a mutually satisfactory manner for thirty (30) days. If such
efforts do not result in mutually satisfactory resolution of the dispute, the
matter shall be handled by arbitration in accordance with Section 8.2.

                                    4 of 7
<PAGE>

   8.2 Any arbitration shall be conducted in Cleveland, Ohio in accordance
with the Commercial Dispute Resolution Procedures of the American Arbitration
Association and in the English language. The arbitrators shall include one
nominee of CCF and one nominee of OPTIONEE, and a third person selected by
said nominees. The parties agree that any arbitration panel shall include
members knowledgeable as to evaluation of the biotechnology industry.
Judgment upon the award rendered may be entered in the highest court or
forum, state or federal, having jurisdiction; provided however that the
provisions of this Section 8 (Dispute Resolution) shall not apply to any
dispute or controversy as to which any treaty or law prohibits such
arbitration,

   8.3 Notwithstanding the foregoing, nothing in this Section 8 shall be
construed to waive any rights or timely performance of any obligations
existing under this Agreement.

9.   ADDITIONAL PROVISIONS
     ---------------------

   9.1 Use of Parties' Names. Each Party agrees that it shall not use in any
       ----------------------
way the name or logo of the other Party without the prior consent of the
Party whose name is to be used.

   9.2 Independent Contractors. The Parties hereby acknowledge and agree that
       ------------------------
each is an independent contractor and that no Party shall be considered to be
the agent, representative, master or servant of any other Party for any
purpose whatsoever, and that no Party has any authority to enter into a
contract, to assume any obligation or to give warranties or representations
on behalf of any other Party. Nothing in this relationship shall he construed
to create a relationship of joint venture, partnership, fiduciary or other
similar relationship between or among the Parties,

   9.3 Indemnification OPTIONEE shall indemnify, hold harmless and defend CCF
       ---------------
and its respective trustees, officers, employees and agents (the
"Indemnitees") against any and all claims and suits of third parties ("Third
Party Claims"), and any damages, costs, fees, and expenses incurred by the
Indemnitees in connection with such Third Party Claims, resulting from or
arising out of this Option Agreement (each a "Loss"). OPTIONEE shall have no
obligation to indemnify any Indemnitees to the extent that a Loss arises out
of the gross negligence or intentional misconduct of an Indemnitee or the
breach of this Agreement by an Indemnitee.

   9.4 Representations and Warranties. Each Party represents and warrants
       -------------------------------
that it has the right, power and authority 1.0 enter into this Agreement. CCF
represents and warrants to OPTIONEE that it owns the Licensable Technology.
CCF represents that to its knowledge, as of the Effective Date of this
Agreement, there are no third party infringement claims against the Licensed
Patents.

   9.5 Disclaimer of Further Warranties. Other than as specifically provided
       ---------------------------------
in section 9.4, CCF makes no warranties or representations, express or
implied, with respect to the Licensable Technology including, but not limited
to, warranties of fitness or merchantability.

9.6 Non-Waiver. The Parties covenant and agree that if a Party fails or
    -----------
neglects for any reason to take advantage of any of the terms providing for
the termination of this Agreement or if a Party, having the right to declare
this Agreement terminated, shall fail to do so, any such failure or neglect
by such Party shall not be a waiver or be deemed or be construed to be a
waiver of any cause for the termination of this Agreement subsequently
arising, or as a waiver of any of the terms, covenants or conditions of this
Agreement or of the performance thereof None of the terms, covenants and
conditions of this Agreement may be waived by a Party except by its written
consent.

                                    5 of 7
<PAGE>

   9.7 Confidentiality. CCF and OPTIONEE agree for the Term and three (3)
       ----------------
years thereafter to hold all Confidential Information in confidence, and to
use the same only in accordance with this Agreement, unless required to do so
by federal or stale securities laws. OPTIONEE shall have the right to share
Confidential Information with affiliates, partners, and consultants, provided
such third party enters into a confidentiality agreement with OPTIONEE having
terms at least as protective as set forth in this Agreement. Except as
required by applicable law, CCF and the OPTIONEE will hold, and will cause
its respective directors, officers, employees, accountants, counsel,
financial advisors and other representatives and affiliates to hold, any
nonpublic information in confidence.

   9.8 Publications and Copyrights. CCF will be free to publish the results
       ----------------------------
of its research during the Term of this Agreement.

   9.9 Reformation. The Parties hereby agree that no Party intends to violate
       ------------
any public policy, statutory or common law, rule, regulation, treaty or
decision of any government agency or executive body thereof of any country or
community or association of countries, and that if any word, sentence,
paragraph or clause or combination thereof of this Agreement is found, by a
court or executive body with judicial powers having jurisdiction over this
Agreement or any of the Parties hereto, in a final, unappealable order to be
in violation of any such provision in any country or community or association
of countries, such words, sentences, paragraphs or clauses or combination
shall be inoperative in such country or community or association of
countries, and the remainder of this Agreement shall remain binding upon the
Parties hereto.

   9.10 Execution in Counterparts. This Agreement may be executed in one or
        --------------------------
more counterparts, each of which shall be deemed to be an original and
executed versions sent by facsimile transmission shall also be deemed to be
originals.

   9.11 Disclaimers. The parties acknowledge and agree that, unless and until
        ------------
the Option is exercised, neither OPTIONEE nor any affiliate of OPTIONEE has
any right or interest in the Licensable Technology.

   9.12 Governing Law This Agreement shall he governed by the laws of the
        -------------
State of Ohio.

   9.13 Press Releases. Both OPTIONEE and CCF will not, without the other
        ---------------
party's prior review and express written consent, issue any press release, or
issue or make any other public comment, or publish or broadcast any
advertisement in any media, or disseminate any sales promotion or
solicitation materials, that in any way refers to the other party, or any
subsidiary or affiliate of the other party, or to the specific terms of this
Agreement unless such item is substantially similar to that which has already
been approved by the other party.

   9.14 Access to Records. If Section 952 of the Omnibus Reconciliation Act
        ------------------
of 1980, which amended Section l861(v)(1) of the Social Security Act, and the
regulations promulgated there under, applies to this Agreement, each party
will make available to the Secretary of Health and Human Services, and to the
Comptroller General of the United States upon written request, such books,
documents and records necessary to verify the nature and extent of the costs
of the services provided hereunder. Access will be granted until the
expiration of four (4) years after the furnishing of services hereunder.
Access will also be granted to any books, documents or records related to
this Agreement between a party and organizations related to that party, but
only an as needed basis.

   9.15 Compliance with Laws. By entering into this Agreement, the parties
        ---------------------
specifically intend to comply with all applicable laws, rules and regulations
as they may be amended from time to time. In the event that any part of this
Agreement is determined to violate federal, state, or local laws, rules, or

                                    6 of 7
<PAGE>

regulations, the parties agree to negotiate in good faith revisions to the
provision or provisions that are in violation. In the event the parties are
unable to agree to new or modified terms as required to bring the entire
Agreement into compliance, either party may terminate this Agreement without
penalty upon thirty (30) days written notice to the other party.

   9.16 Debarment. IVPSA hereby represents and warrants that it has not been
        ----------
debarred, suspended, excluded or otherwise determined to be ineligible to
participate in federal healthcare programs (collectively, "Debarred") and
acknowledges that CCF shall have the right to terminate this Agreement
immediately in the event that IVPSA is Debarred.

   IN WITNESS WHEREOF, the Parties hereto have executed and delivered this
Agreement in multiple originals by their duly authorized officers and
representatives on the respective dates shown below, hut effective as of the
Agreement Date.

IVPSA                                  THE CLEVELAND CLINIC FOUNDATION

By: /s/ T. J. Jesky                    By: /s/ Michael P. O'Boyle
    ---------------                        ----------------------

Name:   T. J. Jesky                      Name: Michael P. O'Boyle
    ---------------                        ----------------------

Title: President/CEO                   Title: Chief Operating Officer
       -------------                          -----------------------

Date: March 20, 2007                   Date: 3-27, 2007
      --------------                         ----------

                                               APPROVED AS TO FORM
                                                  CCF-OFFICE OF
                                                 GENERAL COUNSEL
                                                      BY KDS
                                                         ---
                                                   DATE 3/26/07
                                                        -------
                                                   CMSI#
                                                         ------

                                     7 of 7
<PAGE>

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00125-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00125-of-00352.parquet"}]]